Published in Cancer Weekly, November 15th, 1999
"IL-2 and (beta)-IFN are biologic agents with antitumor activity observed in preclinical models," stated W.J. Tester and colleagues from the Albert Einstein Cancer Center, Pennsylvania. "Some studies of patients with advanced non-small cell lung cancer treated with IL-2 report relatively long survival, despite low response rates."
Tester et al. published the results of their study in the journal Lung Cancer ("A Randomized Phase II Study of Interleukin-2...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.